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1. Introduction
  Diabetes is a clinical common disese. Lifestyle changes 
and the aging process induce a rising trend of diabetes 
year by year, which has become a global public health 
problem[1-3]. Diabetic retinopathy (DR) is a serious 
complication of diabetes. Its pathogenesis is not fully 
clear. It is said that DR is the result of many factors, and 
can lead permanent vision loss. The important step is the 
hyperglycemia, which causes the pathological change of 
hypoxia[4]. It have been reported that hypoxia inducible 
factor-1毩 (HIF-1毩) and vascular endothelial growth factor 
(VEGF) play an important role in the pathogenesis of DR[5-7]. 
This study aimed to observe the expression of HIF-1毩 and 
VEGF in DR induced by STZ. We selected 120 SD rats to set 
up DM model, then observed pathological change of lens 
and retina respectively in 1, 3 and 6 months after injection. 
The results reported as follows.
2. Materials and methods 
2.1. Experimental animals
  A total of 120 male and clean SD rats were selected, which 
were purchased from Laboratory Animal Center, Tianjin 
Medical University. They weighted (241.3依16.5) g, and were 
fed free with food and water. The experimental process 
strictly followed “Regulations of Experimental Animals”.
2.2. Reagent and instrument
  Rabbit anti rat HIF-1毩 antibodies, rabbit anti mouse 
VEGF antibodies and STZ (Sigma company, USA); 
UltraSensitive SP allergic kit (Fuzhou Wallace New 
Biological Company); RNA extraction kit and Trizol Reagent, 
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Taq DNA polymerase, dNTPs, (Fermentas company, USA); 
PCR Marker of New England [New England biological 
technology (Beijing) co., LTD.] production. PCR primers 
(Invitrogen company, USA); Optical microscope BH-2 
OLMPUS; Uv spectral analyzer (DU-800) (American beckman 
coulter co., LTD.); GeneAmp type 9700 PCR amplification 
(Applied Biosystems, USA); Gel imaging analysis system for 
Gel DOC2000 (Bio-Rad company, USA); One Touch 栻 J&J 
blood glucose meter (Shanghai).
2.3. Method
  A total of 120 SD rats were randomly divided into trial 
group and control group with 60 in each. STZ (pH 4.4, 1%) 
i.p. (60 mg/kg) was used in the trial group to establish the 
DM model, after starving for 10 h. Citrate buffer salt of same 
amount was used i.p to the control group, success criteria 
of DM mold is tail blood ≥16.7 mmol/L 72 h. 1, 3 and 6 
months after injection. A total of 20 rats were sacrificed in 
each group to exact the eyes. The eyeball wall was 0.5 mm 
behind the blade side in left eye, followed by separation 
of the retina, formalin fixing, conventional embedding and 
sectioning. Blunt dissection detachment was performed in 
the right eye retina at -80 ℃ liquid nitrogen for further total 
RNA extraction. The expression of HIF-1毩 and VEGF in the 
rat retina tissue were observed using immunohistochemistry, 
strictly following the operation instruction. Slices were 
dewaxed conventionally, hydrated followed by washed in 
PBS for 3 min. After heating repair, it was washed again 
for 5 min. Each section was added with 1 drop peroxidase 
blockers, washed with PBS for 3 min; 1 drop of goat serum 
blocking buffer was added, and it was placed for 20 min at 
room temperature. Excess serum was removed, and added 
with 1:100 dilution of HIF-1毩 and VEG at 37 ℃ for 1 h. It 
was added with 1 drop of biotin labeled antibody after PBS 
washing; then was added with 1 drop of Streptomyces, anti-
biotin peroxidase solution at room temperature for 10 min. 2 
drops of DAB solution was added at room temperature for 3 
to 10 min for the microscopic observation. 
2.4. Criteria
  Four splices from each specimen was selected, and five 
vision areas were randomly taken.  At least 100 cells was 
calculated. Positive cells positive expression rate was 
evaluated, the ratio less than 5% was expressed as negative. 
HIF-1毩 mainly is located in nucleus as tan particles, VEGF 
is mainly expressed in the cytoplasm as tan particles.
2.5. Statistical analysis
  SPSS12.0 statistics software was used for processing data, 
and they were expressed as (x 依 s). It was analyzed by t 
test. P < 0.05 was considered as statistically significant 
difference.
3. Results
3.1. Expression of HIF-1毩 and VEGF in different time 
points 
  Expression of HIF-1毩 and VEGF were negative in the 
control group; expression of HIF-1毩 and VEGF protein 
in retinal tissue were weak after 1 month of DR mold 
formation in observation group, and it showed a progressive 
enhancement along with the progression in different parts. 
Differences between groups were significant (P<0.05), the 
results are shown in Table 1.
3.2. Absorbance ratio of HIF-1毩 mRNA and VEGF mRNA 
at different time points
  Absorbance ratio of HIF-1毩 and VEGF were negative or 
weak in the control group; absorbance ratio of HIF-1毩 and 
VEGF protein in retinal tissue in observation group showed 
Table 1
Expression of HIF-1毩 and VEGF in different time points.
Groups
1 month 2 months 3 months
HIF-1毩 VEGF HIF-1毩 VEGF HIF-1毩 VEGF
Observation group 10.49依2.12*   9.71依1.29* 35.66依3.3* 40.78依4.11* 88.73依6.22* 92.87依5.12*
Control group 2.61依0.43 2.32依0.58   2.09依0.53  1.82依0.59  2.12依0.45  1.78依0.63
Note: * compared with controls, P< 0.05.
Table 2
Absorbance ratio of HIF-1毩 mRNA and VEGF mRNA at different time points.
Groups
1 month 2 months 3 months
HIF-1毩 VEGF HIF-1毩 VEGF HIF-1毩 VEGF
Observation group  0.46依0.19*  0.49依0.17*  0.55依0.19*  0.59依0.21*  0.77依0.23*  0.91依0.19*
Control group 0.75依0.05 0.35依0.01 0.69依0.15 0.41依0.10 0.64依0.06 0.36依0.01
Note: * compared with controls, P< 0.05.
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a progressive enhancement with significant differences 
between groups (P<0.05), the results are shown in Table 2.
3.3. Immunohistochemical results of rats retinal tissue 
between two groups 
  There were no positive expression of HIF-1毩 and VEGF 
in the control group, expression of HIF-1毩 and VEGF in 
retinal tissue in observation group showed a progressive 
enhancement with significant differences between groups 
(P<0.05), the results are shown in Figure 1.
C                                                                        D
A                                                                        B
Figure 1. Immunohistochemical results of rats retinal tissue between 
two groups.
A: Control group, B: Observation group (1 month), C: Observation 
group (3 months), D: Observation group (6 months).   
4. Discussion
  DR is a serious fundus complications of diabetes during late 
phase. Its pathogenesis basis is hyperglycemia, which can 
induce the capillary basement membrane thicken, chronic 
ischemic retinal tissue hypoxia[8-13], lextracellular matrix 
and basement membrane dissolved, fade, and cell migration, 
proliferation and lead to new retinal angiogenesis[14-16].
  Studies have found that, in the process of starting and 
development of diabetic retinopathy, HIF-1毩 and VEGF 
play an important role in different phases[17-21]. HIF-1毩 is 
the key factor of  regulating metabolism of oxygen in cells, 
which has stable effect on cell hypoxia[22-25]. Hypoxia can 
trigger the cells signaled by receptor molecules on the cell 
membrane. It s many changes in gene expression in the 
cell, inducing complex stress responses to hypoxia, such 
as coding VEGF, erythropoietin, tyrosine hydroxylase and 
enzyme gene. They were involved in glycolytic activity 
during hypoxia, in order to make the body to adapt to the 
body’s internal environment. This study found that in the 
control group rats, in normal retina tissue, HIF-1毩 is not 
expressed. HIF-1毩 was expressed clearly in observation 
group rats. It shows that oxygen deficit plays an important 
role in the process of the onset of DR. Expression of HIF-1
毩 is enhanced with the progression of DR. It shows that 
hypoxia develops along with the progression of DR. VEGF 
is the most powerful angiogenic factor, which can induce 
formation of retinal neovascularization. Its expression 
is regulated by the multiple factors, hypoxia is the most 
powerful inducing factors[26-29]. In this study, the expression 
of VEGF in rat retina is obvious in the observation group. It 
is enhanced with the course development[30,31]. It shows that 
VEGF plays an important role in the pathogenesis of DR. 
The ischemic retinal HIF-1毩 showed that its expression 
increased temporarily and space-specific with expression 
increment of VEGF. So this result match the assumption 
that HIF-1毩 will play an important role in the increment of 
VEGF expression[32-34].
  This study results showed that expression of HIF-1毩 and 
VEGF was positively correlated with DR severity. HIF-1
毩 and VEGF play an important role in the process of in 
DR induction and vascularization. Moderate adjustment 
expression of HIF-1毩 and VEGF has positive significance 
to the prevention and treatment of DR.
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